November 23 Biotech Update

The market dynamics remain the same.  We are entering what tends to be a seasonally positive period of the year, which might add some tailwind to the broader market.  While I still think the market is going to focus on the prospects of the vaccine coming next year as opposed to the out of control […]

November 20th Biotech Update

I think choppy might have been the best description of the market at this point.  This makes sense give the competing influences on both the market and economy.  I would not be surprised to see this chop continue or perhaps even see some consolidation.  The broader market seems in a little more precarious position than […]

November 19th Biotech Update

Nothing crazy happening in the market at this point.  I do not see anything that compelling low or high and I think the market continues to struggle with the hope of the vaccines versus the pain of an out of control spread.  There is likely a point where the immediate term gets so bad that […]

November 18th Biotech (and MLP) Update

So the market continues to look good including the sector that is pushing all time highs.  While I often say the trend is your friend (and it is), it might also be time to pull out another saying.  When markets are making all time highs, the most likely outcome is to continue to make marginal […]

November 16th Biotech Update

Another start to the week with some more vaccine announcements (positive).  It was good to see more positive vaccine data but it does not change the dynamic that I see with the market.  There appears to be a real light at the end of the tunnel but the path to the end will be very […]

November 13th Biotech Update

So its been a decent week and hopefully we can end on a strong note.  Not a lot of news to move the market or sector and perhaps that means we get a decent look at the underlying sentiment of the market.  We are past the major catalysts of November and there is really not […]

November 12th Biotech Update

The market continues to move along it sort of the honeymoon period post election risk reduction.  I still worry about the pandemic as cases continue to grow unabated in the EU and US.  Is it possible that the market (and Americans) simply do not care about it anymore and have simply accepted the death as […]

November 11th Biotech Update

Below are my comments on the guidelines that you can forward along.   So it looks like the market has digested the outcome of the election for the most part.  I still think there is going to be a tug of war in terms of COVID with the vaccine news pushing the post-COVID names but […]

November 9th Biotech Update

We do not have merger Monday, so I suspect the market will be disappointed.  I joke of course as this is going to be a massive relief rally on the news of the PFE vaccine.  While there will certainly be a rally that raises almost everyone, there will likely be rotations out of COVID treatment […]

November 6th Biotech Update

It seems like the election is all but over.  The votes have turned and clearly point to a Bide victory and as of writing speculation is that Trump will admit defeat.  Of course, Trump does not have to concede for Biden to win but it would assuage investors and remove the last bit of risk […]

November 5th Biotech Update

While we clearly do not have a clear winner from the election, it at least looks like the market has decided where the election is going.  If there was uncertainty over the outcome, then the market would not have rallied and volatility would not have dropped.  Given the pace of vote counting, it looks like […]

November 4th Biotech Update

The election is (sort of) over.  While it ended up being closer than the polls indicated, it appears that Biden will win barring some unprecedented court decision to invalidate large numbers of legally cast votes.  The closeness of the election, however, makes the Senate now lean Republican.  I suspect both Georgia contests will have to […]

November 2nd Biotech Update

This is the literal calm before the storm.  The election is tomorrow and the adu AdCom is Friday.  Plus, we still have a number earnings coming this week as well.  Even with all of that news the week starts off with basically nothing that meaningful so there is not much to say.  That is not […]

Perimeter, OTIS – Optical Coherence Tomography and the Future of AI in Surgical Breast Cancer Treatment

Perimeter Medical Imaging AI (PINK.v) is a Toronto-based company with U.S. headquarters in Dallas, Texas developing advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during cancer excision surgery. Perimeter has an innovative FDA 510(k) approved medical device, soon to launch commercially, that is ready to disrupt breast cancer surgery […]

October 30 Biotech Update

I said that a kick was possible for the sector and it could be pulling one off.  Yesterday ended up better than I expected and was the start of that save but the market remains in a precarious position with anxiety over the election potentially overwhelming everything today.  Of course, the consensus seems to be […]

October 29th Biotech Update

As awful as the day was yesterday, the sector is not quite broken.  This is not to say that things look great but a reversal and green close today could save it.  Another day lower and we can call the trend as it would be a potentially lower low establishing.  I am not very optimistic […]

October 28th Biotech Update

Not a great start to the week (or continuation of the week) as the market and sector continue to struggle.  Given all of the potential news makers in the next couple weeks it is difficult to completely attribute the move solely to one factor.  My mantra has been that the trend is your friend and […]